Caribou Biosciences Inc.

Company Snapshot

Founded: 2011

Entity Type: Public

Employees: 97

Region: U.S.

Revenue: $11.2 Millions

Revenue Year: 2025

Headquarter: California, U.S.

Key Geographics: U.S., Rest of World

Corporate Address: 2929 7th Street Suite 105, Berkeley California 94710 U.S. Tel. +1-510-982-6030 www.cariboubio.com

Company Overview

Caribou Biosciences Inc. is a biotechnology company focused on the development of CRISPR genome editing technologies and advancements in nucleic acid biology. The company’s genome-editing platform, featuring chRDNA (CRISPR hybrid RNA-DNA) technology, allows for more precise genome editing, creating cell therapies designed to enhance activity against diseases. It is advancing a pipeline of allogeneic, or off-the-shelf, cell therapies, including chimeric antigen receptor (CAR)-T and CAR-natural killer (CAR-NK) cell platforms, to provide readily available treatments. Caribou’s focus is in four key areas: therapeutics, agricultural biotechnology, biological research, and industrial biotechnology.

Financial Highlights (FY 2025)

Net Revenue: ***

Total Current Liabilities: ***

Total Current Assets: ***

R&D expenses: ***

Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Caribou Biosciences Inc. In Reports

Genome Editing: Technologies and Global Markets

BCC Research Market Analyst says global market for genome editing is expected to grow from $10.8 billion in 2025 and is projected to reach $23.7 billion by the end of 2030

CRISPR Technology: Global Markets

BCC Research Market Analyst says global market for CRISPR technology was valued at $3.4 billion in 2023 & is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029.

Gene Editing Therapeutics Market

BCC Research Market Analyst says gene editing therapeutics market is estimated to be $11 million in 2024 and is forecasted to grow at a CAGR of 147% to reach a value of $1.0 billion by end of 2029.

View All Reports

Caribou Biosciences Inc. In News

Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows - Yahoo Finance

Yahoo Finance - May 31, 2026

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network

Investing News Network - May 28, 2026

Caribou Biosciences, Inc. Announces Acceptance of Two Oral Presentations at the 2026 European Hematology Association Annual Meeting - Quiver Quantitative

Quiver Quantitative - May 12, 2026

Caribou secures FDA alignment on phase 3 trial, sees cash into 2H 2027 - Stock Titan

Stock Titan - May 07, 2026

Read All News

Company's Business Segments

Cell Therapies : The company provides genome-edited allogeneic cell therapies and platform for devastating human diseases.

Applications/End User Industries

Biopharmaceutical

Healthcare

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment